Key facts
- This page summarizes BVF PARTNERS L P/IL's Form 4 filing for 4D Molecular Therapeutics, Inc. (FDMT).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 13 Nov 2024, 16:33.
BVF PARTNERS L P/IL - 08 Nov 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)
- Reporting relationship
- Other*
- Issuer ticker
- FDMT
- Reported as of
- 08 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Nov 2024, 16:33:15 UTC
- Prior SEC filing
- 31 Oct 2024
- Next SEC filing
- 04 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
BVF PARTNERS L P/IL filed Form 4 for 4D Molecular Therapeutics, Inc. (FDMT) on 13 Nov 2024.
Change
- Previous filing in this sequence was filed on 31 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FDMT
transaction
Common Stock, $0.0001 par value
Other
- Transaction value
- Shares
- -3,062,000
- Change %
- -79%
- Price
- Shares after
- 830,237
- Date
- 08 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
FDMT
transaction
Common Stock, $0.0001 par value
Other
- Transaction value
- Shares
- -2,378,000
- Change %
- -78%
- Price
- Shares after
- 662,970
- Date
- 08 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F4
FDMT
transaction
Common Stock, $0.0001 par value
Other
- Transaction value
- Shares
- -240,000
- Change %
- -73%
- Price
- Shares after
- 87,911
- Date
- 08 Nov 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FDMT
transaction
Derivative
Pre-Funded Warrant
Other
- Transaction value
- Shares
- +3,062,000
- Change %
- Price
- Shares after
- 3,062,000
- Date
- 08 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 3,062,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F3, F6
FDMT
transaction
Derivative
Pre-Funded Warrant
Other
- Transaction value
- Shares
- +2,378,000
- Change %
- Price
- Shares after
- 2,378,000
- Date
- 08 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 2,378,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F4, F6
FDMT
transaction
Derivative
Pre-Funded Warrant
Other
- Transaction value
- Shares
- +240,000
- Change %
- Price
- Shares after
- 240,000
- Date
- 08 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock, $0.0001 par value
- Underlying amount
- 240,000
- Exercise price
- $0.000100
- Footnotes
- F1, F2, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
BVF PARTNERS L P/IL is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Footnote F2
On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.
Footnote F3
Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
Footnote F4
Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
Footnote F5
Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
Footnote F6
Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise.